The High Authority for Health (HAS) was to decide the fate of the 533,000 people under the age of 55 who received a first dose of AstraZeneca vaccine, but could no longer receive the second planned.
The experts reminded us on Friday morning: unthinkable to go back on the recommendation not to inject the AstraZeneca vaccine to people under 55 years old, the very low number of second doses delivered in France (367 to March 28, 2021) not allowing to judge if the latter is less, more or as much at risk of thromboembolism as the first.
But there is no question of leaving people with a single injection, the immunity conferred by a single dose being too uncertain in the long term ...
To discover
Test, isolation: the procedure to follow in the event of a suspicion of Covid-19
A lead to explain the rare thromboses linked to the AstraZeneca vaccine
To read also:
AstraZeneca: "Many arguments in favor" of a second different dose, according to the HAS
The HAS has therefore chosen: the second dose will be with a messenger RNA vaccine (Pfizer / BioNTech or Moderna), a so-called “heterologous prime-boost” scheme.
A decision contested, in particular by the World Health Organization which estimated Friday that for lack of
"adequate data"
, the experts could not
This article is for subscribers only.
You have 71% left to discover.
Subscribe: 1 € the first month
Can be canceled at any time
I ENJOY IT
Already subscribed?
Log in